CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
722.39MEUR843.94M · vs all stocks (USD)
Revenue (TTM)
70.84MEUR82.77M · vs all stocks (USD)
Profit Margin
-121.35%vs Biotechnology peers
Beta
1.14xvs all stocks
52-Week Change
280.88%vs all stocks
Market Capitalization
722.39MEUR843.94M · vs all stocks (USD)
Enterprise Value
735.93MEUR859.75M · vs all stocks (USD)
Forward P/E
17.19xvs Biotechnology peers
Price to Sales (TTM)
10.18xvs Biotechnology peers
Enterprise to Revenue
10.39xvs Biotechnology peers
Enterprise to EBITDA
-14.22xvs Biotechnology peers
Profit Margin
-121.35%vs Biotechnology peers
Operating Margin
-151.88%vs Biotechnology peers
Return on Assets (TTM)
-21.57%vs Biotechnology peers
Revenue (TTM)
70.84MEUR82.77M · vs all stocks (USD)
Revenue per Share (TTM)
1.42EURUpdated Aug 21, 2026Quarterly Revenue Growth
268.20%vs Biotechnology peers
Gross Profit (TTM)
70.84MEUR82.77M · vs all stocks (USD)
EBITDA (TTM)
-51.74MEUR-60.44M · vs all stocks (USD)
Net Income (TTM)
-85.97MEUR-100.43M · vs all stocks (USD)
Operating Cash Flow (TTM)
-26.24MEUR-30.66M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-59.39MEUR-69.39M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.00EURUpdated Aug 21, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
65.43MEURFY2025 · Dec 31, 2025Cost of Goods Sold
302.00KEURFY2025 · Dec 31, 2025Gross Profit
65.13MEURFY2025 · Dec 31, 2025Operating Income
-53.57MEUR-62.58M · vs all stocks (USD)
Pre-tax Income
-86.50MEURFY2025 · Dec 31, 2025Income Tax Expense
-531.00KEURFY2025 · Dec 31, 2025Net Income
-85.97MEURFY2025 · Dec 31, 2025EBIT
-85.29MEURFY2025 · Dec 31, 2025EBITDA (Income Statement)
-83.38MEURFY2025 · Dec 31, 2025Research & Development
103.46MEURFY2025 · Dec 31, 2025Other Operating Expenses
11.05MEURFY2025 · Dec 31, 2025Non-operating Interest Income
1.49MEURFY2025 · Dec 31, 2025Non-operating Interest Expense
1.21MEURFY2025 · Dec 31, 2025Net Income from Continuing Operations
-85.97MEURFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00EURFY2025 · Dec 31, 2025Operating Cash Flow
-88.75MEURFY2025 · Dec 31, 2025Free Cash Flow
-90.10MEURFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
101.09MEURFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-85.97MEURFY2025 · Dec 31, 2025Stock-based Compensation
308.00KEURFY2025 · Dec 31, 2025Other Non-cash Items
29.64MEURFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-32.73MEURFY2025 · Dec 31, 2025Capital Expenditures
-1.35MEURFY2025 · Dec 31, 2025Net Intangibles (CF)
-2.03MEURFY2025 · Dec 31, 2025Purchase of Investments
-250.00KEURFY2025 · Dec 31, 2025Sale of Investments
0.00EURFY2025 · Dec 31, 2025Net Investing Cash Flow
-1.60MEURFY2025 · Dec 31, 2025Long-term Debt Issuance
130.02MEURFY2025 · Dec 31, 2025Long-term Debt Payments
-63.12MEURFY2025 · Dec 31, 2025Other Financing Charges
-13.44MEURFY2025 · Dec 31, 2025Net Financing Cash Flow
53.52MEURFY2025 · Dec 31, 2025Shares Outstanding
50.04MSharesUpdated Aug 21, 2026Float Shares
41.07MSharesUpdated Aug 21, 2026% Held by Insiders
13.22%vs all stocks
% Held by Institutions
9.58%vs all stocks
Total Cash (MRQ)
101.09MEUR118.10M · vs all stocks (USD)
Total Cash per Share (MRQ)
2.02EURUpdated Aug 21, 2026Total Debt (MRQ)
150.69MEUR176.04M · vs all stocks (USD)
Current Ratio (MRQ)
2.00xvs Biotechnology peers
Book Value per Share (MRQ)
-0.4510EURUpdated Aug 21, 2026Total Assets
159.04MEUR185.80M · vs all stocks (USD)
Total Current Assets
144.28MEURFY2025 · Dec 31, 2025Total Liabilities
181.58MEURFY2025 · Dec 31, 2025Total Non-current Assets
14.76MEURFY2025 · Dec 31, 2025Total Non-current Liabilities
109.27MEURFY2025 · Dec 31, 2025Total Current Liabilities
72.31MEURFY2025 · Dec 31, 2025Cash
8.59MEURFY2025 · Dec 31, 2025Cash Equivalents
92.50MEURFY2025 · Dec 31, 2025Cash & Cash Equivalents
101.09MEURFY2025 · Dec 31, 2025Accounts Receivable
31.51MEURFY2025 · Dec 31, 2025Inventory
4.00KEURFY2025 · Dec 31, 2025Accounts Payable
15.89MEURFY2025 · Dec 31, 2025Short-term Debt
42.90MEURFY2025 · Dec 31, 2025Other Current Liabilities
-1.00KEURFY2025 · Dec 31, 2025Long-term Debt
107.79MEURFY2025 · Dec 31, 2025Other Non-current Liabilities
1.00KEURFY2025 · Dec 31, 2025Common Stock (Book)
12.51MEURFY2025 · Dec 31, 2025Retained Earnings
-475.78MEURFY2025 · Dec 31, 2025Total Shareholders' Equity
-22.54MEUR-26.33M · vs all stocks (USD)
52-Week Low
3.05EURUpdated Aug 21, 202652-Week High
15.48EURUpdated Aug 21, 202652-Week Change
280.88%vs all stocks
Beta
1.14xvs all stocks
50-Day MA
12.35EURUpdated Aug 21, 2026200-Day MA
8.32EURUpdated Aug 21, 2026Avg 10-Day Volume
247.07KSharesUpdated Aug 21, 2026Avg 30-Day Volume
340.80KSharesUpdated Aug 21, 2026Diluted EPS (TTM)
-1.72EURUpdated Aug 21, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Anhui Hongyu Wuzhou Medica Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Chengdu Shengnuo Biotech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
R&G Pharmastudies Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Pharming Group N.V.
Tier 1ProductionApproval-Gated PipelineRule
Shouyao Holdings Beijing Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Luoxin Pharmaceuticals Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Solid Biosciences Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Replimune Group Inc.
Tier 1ProductionApproval-Gated PipelineRule
Gansu Longshenrongfa Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
HK inno.N Corporation
Tier 1ProductionApproval-Gated PipelineRule